TSX runs higher on rate cut expectations
ENGLEWOOD, CO—MVM Partners, LLC, a significant shareholder in Paragon 28 , Inc. (NYSE:FNA), recently sold over 1 million shares of the company’s common stock, as disclosed in a recent SEC filing. The transaction, which took place on March 13, 2025, involved the sale of 1,044,295 shares at a weighted average price of approximately $13.04 per share, resulting in a total transaction value of $13.6 million. The sale comes as the stock trades near its 52-week high of $13.13, having gained an impressive 76% over the past six months. According to InvestingPro analysis, the stock appears overvalued at current levels.
Following this sale, MVM Partners retains ownership of 7,810,588 shares of Paragon 28, held indirectly through various entities. The shares sold were part of a series of transactions executed at prices ranging from $13.01 to $13.065 per share. For deeper insights into insider transactions and comprehensive analysis, InvestingPro subscribers can access detailed research reports covering over 1,400 US stocks.
Paragon 28, based in Englewood, Colorado, specializes in surgical and medical instruments, and its stock is actively traded on the New York Stock Exchange under the ticker symbol FNA. The company, with a market capitalization of $1.1 billion, has demonstrated strong revenue growth of 18% over the last twelve months, though it remains unprofitable. The company maintains a healthy liquidity position with a current ratio of 3.51.
In other recent news, Paragon 28 announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, a significant step in its acquisition by Zimmer Biomet Holdings (NYSE:ZBH). The merger, valued at approximately $1.2 billion, includes an upfront payment of $13 per share and a contingent value right that could add an additional $1 per share if revenue milestones are met. On the analyst front, Stephens downgraded Paragon 28 from Overweight to Equal Weight, citing the recent strong performance of its stock and the anticipated completion of the acquisition. Similarly, Needham downgraded the stock from Buy to Hold, reflecting the low likelihood of a higher bid emerging.
JMP Securities, however, maintained a Market-Outperform rating for both companies, highlighting Paragon 28’s strong financial growth, including achieving EBITDA positivity in the third quarter of 2024. Paragon 28’s preannouncement of its fourth-quarter 2024 revenue, expected to be between $71.5 million and $71.8 million, represents an 18-19% year-over-year increase, surpassing the consensus estimate. For the full year 2024, the company anticipates revenue between $255.9 million and $256.2 million, marking a similar growth rate. Needham analysts reaffirmed a Buy rating earlier, noting the company’s positive trajectory and potential for future growth. These developments reflect significant movements in Paragon 28’s business landscape and financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.